Clinical Trials – Surufatinib for Neuroendocrine Cancer (SANET)

Clinical Trials – Surufatinib for Neuroendocrine Cancer (SANET)

Clinical Trials
Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email An extremely interesting drug in the pipeline which has been featured at ENETS, NANETS, ESMO and ASCO. Chi-Med will submit a New Drug Application (NDA) to the US FDA for them to consider approval.  It is anticipated the NDA will arrive in FDA by the end of this year. The story follows PRESS RELEASE: LONDON, June 01, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib for the treatment of patients with advanced neuroendocrine tumors (“NET”).  Chi-Med has reached an agreement with the FDA that the…
Read More